The National Cancer Institute (NCI) awarded a $701,876 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Weill Medical College of Cornell University to develop a novel high-throughput technology called SatSeq. This innovative approach couples single-cell sequencing with saturation mutagenesis and DNA barcoding to systematically map the structure-function landscape of multimodal proteins, with a focus on the immune regulator STING and its opposing roles in cancer progression. The 5-year project aims to use SatSeq to uncover STING's diverse cellular and in vivo functions, as well as validate the on-target effects of emerging STING modulators in clinical development. This research is expected to expand understanding of STING's complex biology and identify new avenues for patient selection in STING-targeted cancer therapies.
Generated 3/18/25, 3:57 AM